Fig. 5.

Combination of CYT997 and dasatinib exhibits greater inhibitory activity of prostate tumor growth than either treatment alone. a, b When the PC3-derived flank xenografts have been established, NSG mice were randomly divided into four groups (n = 5) for the indicated treatments. Tumor growth was measured by tumor volume (a), and tumor burden at the end of the experiment was calculated as tumor weight (b). c, d Mice were sacrificed on day 42 after treatment, and xenografts were dissected and removed for Western blot with the indicated antibodies (c) and IHC with Ki67 antibody (d). In c, 1 and 2 indicate the tumor samples from two different mice. In d, representative images of IHC are shown in the left panel, and quantitative data of staining intensity are shown in the right panel (n = 10). *p < 0.05; **p < 0.01